Новая технология показала, как опухоль оттесняет ткани и перестраивает сосуды мозга
Новая технология показала, как опухоль оттесняет ткани и перестраивает сосуды мозга poisknews.ru
Новая технология показала, как опухоль оттесняет ткани и перестраивает сосуды мозга poisknews.ru
Chinese Medical Journal evaluates triple regimen for HR+/HER2− advanced breast cancer EurekAlert! Science News Releases
There is no perfect time to start a family as a busy ophthalmologist. However, motherhood is an important job, and women in medicine should never feel the need to apologize for it. “Someone said to me, ‘There is no good time to have a baby except for when it’s the right time for you.’ It’s always going to be hard at…
A new AI-based model can predict where glioblastoma is most likely to return after initial surgery, potentially giving doctors a chance to treat it before it becomes visible on MRI.
NCH Continues its Expansion of Cancer Program with New Specialists and Services South Florida Hospital News
U.S. FDA Accepts sNDA and Grants Priority Review to Bayer’s Lynkuet® (elinzanetant) for a New Indication for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Endocrine Therapy Related to Breast Cancer BioSpace
Oncolytics Biotech Announces Progress in REO 033 Trial, Site Activations and FDA-Aligned Pathway for Pelareorep in Metastatic Colorectal Cancer Quiver Quantitative
Bundled Payments in Community Oncology: Making It Work Oncology News Central
ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer Investing News Network
Men with high-risk prostate cancer have a higher likelihood of residual disease after prostatectomy and may require radiation therapy after surgery, particularly when PSA levels begin to rise. Conventional postprostatectomy radiotherapy (COPORT) is typically delivered over 37 fractions, while hypofractionated…
Alisertib Phase 2 Combo Trial Launches in Small Cell Lung Cancer Targeted Oncology
Siemens Healthineers Launches Accela Radiotherapy System With 60-Second SBRT Capability Pulse 2.0
New CRISPR activation platform uncovers genetic drivers of cancer resistance Drug Discovery News